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also evaluated.
Results: The study was stopped early due to the superiority
of CT. Ninety percent of patients in the CT group did not
experienced OM, compared to 36% and 34% in the Caphosolâ
and SS groups, respectively (P < 0.0001). None of the CT
patients experienced grade 3-4 OM. There was a signiﬁcant
decrement in duration of OM in the CT group compared to
the Caphosolâ group (mean duration [MD] in days 0.8 vs.
4.77; p < 0.001) and the SS group (MD 5.55 days; p < 0.001).
Duration of OMwas shorter in the CT group compared to the
SS group (MD .9 days vs. 3.38 days; p ¼ 0.004) and the
Caphosolâ group (MD 2.97 days; p¼ 0.020). Patients in the CT
group required less use of analgesics when compared with
the SS group (p ¼ 0.007).
Conclusion: CT signiﬁcantly reduces OM incidence, severity
and duration. . Patients who received CT had lower analgesic
requirements than patients who received SS.310
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Fungal colonization may increase the risk for developing
invasive fungal infections(IFI) for patients undergoing stem
cell transplants (SCT). At Northwestern Memorial Hospital a
protocol was initiated in 2005 to administer amphotericin B
decanoate nasal spray to all SCT recipients with fungal nasal
colonization.
Amphotericin B 0.5% nasal spray was given twice daily in
addition to systemic prophylaxis (ﬂuconazole for auto-SCT’s
or voriconazole 200 mg for allo-SCT’s) to all patients with
nasal fungal colonization. Nasal surveillance cultures were
repeated within 7- 30 days of Ampho B initiation. An inde-
pendent expert reviewer was utilized to determine the
presence of IFI according to EORTC criteria.
Amongst1936patients reviewed,117 fungal isolates (62mould
and57yeast )were identiﬁed fromthenaresof109patients (78
auto/31allo). Therewasnosigniﬁcantdifference inage, gender,
diagnosis, transplant or donor type betweenpatientswith and
without nasal fungal colonization. Eight patients had a prior
history of IFI. Nasal surveillance cultures after Ampho B began
showed 100% eradication of all isolates. One breakthrough IFI
was observed amongst the 109 Ampho B treated patients
(Alternia ssp.soft tissue infection in auto-SCT successfully
treated with voriconazole). Systemic Antifungal prophylaxis
waschanged in25patients, primarily for febrileneutropeniaor
liver enzyme abnormalities. Nasal Ampho Bwaswell tolerated
and no patient discontinued use during transplantation.
Intranasal Ampho B effectively eradicates nasal fungal colo-
nization and appears effective in preventing breakthrough
fungal infections in colonized HSCT recipients.311
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